MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a clinical-stage pharmaceutical development company advancing oral drug candidates for neurologic, neuropsychiatric, inflammatory, metabolic and addiction-related disorders. Its pipeline includes Ketamir-2, an NMDA receptor modulator that has completed Phase 1 testing in… From the company’s description.
In fiscal 2025, MIRA Pharmaceuticals, Inc. reported a net loss of $10.44M. Operations used $4.66M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MIRA Pharmaceuticals, Inc. does
In the company’s own words
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a clinical-stage pharmaceutical development company advancing oral drug candidates for neurologic, neuropsychiatric, inflammatory, metabolic and addiction-related disorders. Its pipeline includes Ketamir-2, an NMDA receptor modulator that has completed Phase 1 testing in healthy volunteers and is being developed for neuropathic pain, initially chemotherapy-induced peripheral neuropathy; MIRA-55, a preclinical cannabinoid analog for inflammatory pain and central nervous system conditions; and SKNY-1, a preclinical candidate for weight management and nicotine dependence. The company holds exclusive rights to these candidates in the United States, Canada and Mexico. MIRA acquired SKNY Pharmaceuticals in September 2025, adding the SKNY-1 program. The company reports one pharmaceutical development business, with no reportable segment breakdown provided. Its website is www.mirapharmaceuticals.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- CIK
- 1904286
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MIRA Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MIRA Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MIRA Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MIRA Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MIRA Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”